MATUCCI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.974
EU - Europa 3.795
AS - Asia 2.730
SA - Sud America 335
Continente sconosciuto - Info sul continente non disponibili 94
AF - Africa 67
OC - Oceania 29
Totale 12.024
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.827
RU - Federazione Russa 1.073
IT - Italia 1.025
PL - Polonia 809
SG - Singapore 746
CN - Cina 736
HK - Hong Kong 355
VN - Vietnam 265
BR - Brasile 251
KR - Corea 202
IE - Irlanda 166
SE - Svezia 154
FR - Francia 104
GB - Regno Unito 100
DE - Germania 98
IN - India 89
CA - Canada 85
FI - Finlandia 80
BD - Bangladesh 79
JO - Giordania 49
JP - Giappone 47
ID - Indonesia 46
CH - Svizzera 38
ES - Italia 36
NL - Olanda 32
AR - Argentina 31
AU - Australia 28
MX - Messico 24
BE - Belgio 18
IQ - Iraq 14
UA - Ucraina 14
VE - Venezuela 13
ZA - Sudafrica 13
CO - Colombia 11
NG - Nigeria 11
AE - Emirati Arabi Uniti 10
CI - Costa d'Avorio 10
IL - Israele 10
PK - Pakistan 10
EC - Ecuador 9
JM - Giamaica 9
MA - Marocco 9
PH - Filippine 9
TR - Turchia 9
AT - Austria 8
CL - Cile 8
EG - Egitto 8
CZ - Repubblica Ceca 7
MY - Malesia 7
SA - Arabia Saudita 7
LT - Lituania 6
PY - Paraguay 6
TH - Thailandia 6
TN - Tunisia 6
UZ - Uzbekistan 6
HN - Honduras 5
NP - Nepal 5
BJ - Benin 4
CR - Costa Rica 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
UY - Uruguay 4
AZ - Azerbaigian 3
GR - Grecia 3
GT - Guatemala 3
HU - Ungheria 3
OM - Oman 3
RO - Romania 3
AL - Albania 2
BB - Barbados 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MN - Mongolia 2
NI - Nicaragua 2
PR - Porto Rico 2
PT - Portogallo 2
SN - Senegal 2
SV - El Salvador 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BM - Bermuda 1
BO - Bolivia 1
DK - Danimarca 1
EE - Estonia 1
GE - Georgia 1
IR - Iran 1
KE - Kenya 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
NC - Nuova Caledonia 1
Totale 11.923
Salva come PNG Salva come JPEG
Città #
Santa Clara 816
Warsaw 804
Ashburn 746
Singapore 533
Hong Kong 305
San Jose 287
Fairfield 278
Seoul 202
Milan 190
Hefei 183
Chandler 178
Dublin 166
Beijing 128
Houston 109
Florence 108
Council Bluffs 107
Seattle 107
Wilmington 107
Woodbridge 107
Cambridge 103
Los Angeles 96
Ann Arbor 93
Elk Grove Village 88
Ho Chi Minh City 80
New York 70
Rome 68
Buffalo 64
Altamura 63
Lawrence 63
Moscow 62
Dallas 60
Hanoi 60
Munich 55
Lauterbourg 50
Chicago 45
The Dalles 42
Princeton 39
Shanghai 39
Kent 38
Helsinki 35
Jakarta 33
Mumbai 32
Phoenix 30
Boston 29
Paris 26
Dong Ket 24
Tokyo 24
London 23
Madrid 23
Melbourne 23
Naples 23
San Diego 22
Toronto 21
São Paulo 20
Turku 20
Medford 19
Bern 18
Figino 18
Luni 18
Frankfurt am Main 17
Genoa 17
Boardman 16
Brussels 16
Chennai 15
Zurich 15
Clifton 14
Lappeenranta 14
Bologna 13
Orem 13
Brooklyn 12
Palermo 12
Abuja 11
Bari 11
Montreal 11
Abidjan 10
Atlanta 10
Bengaluru 10
Guangzhou 10
Osaka 10
Johannesburg 9
Philadelphia 9
Tel Aviv 9
Xi'an 9
Charlotte 8
Jacksonville 8
Livorno 8
Norwalk 8
Redondo Beach 8
Turin 8
Da Nang 7
Hải Dương 7
Liverpool 7
Padua 7
Tianjin 7
Biên Hòa 6
Campinas 6
Denver 6
Dhaka 6
Mexico City 6
Miano 6
Totale 7.632
Salva come PNG Salva come JPEG
Nome #
Mepolizumab Reduces Inflammatory Eosinophils in Nasal Polyp Tissue and Restores Histological Alterations 339
Hapten-Specific TH17 Cells in the Peripheral Blood of β-Lactam-Induced AGEP. 328
Immunoglobulin replacement therapy for yellow nail syndrome 314
The in vitro amplification of β-lactam-specific memory t cells improves the diagnostic performance of IGE detection and lymphocyte transformation test 303
Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study 275
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies 264
Concomitant Bilastine and Montelukast as Additive Therapy for Seasonal Allergic Rhinoconjunctivits and Mild-to-Moderate Asthma. The SKY Study 261
Efficacy and safety of mepolizumab (Anti-Interleukin-5) treatment in Gleich's syndrome 246
The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999–2019) 246
Urinary rituximab loss and rate of treatment failure in membranous nephropathy 245
High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients 243
Malattia di Anderson-Fabry 233
Biweekly hizentra® in primary immunodeficiency: A multicenter, observational cohort study (IBIS) 231
High serum β-lactams specific/total IgE ratio is associated with immediate reactions to β-lactams antibiotics 229
Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab 225
Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab 217
Miescher's cheilitis: Surgical management and long term outcome of an extremely severe case. 215
Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020 214
Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. 209
The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment 209
Assays and strategies for immunogenicity assessment of biological agents. 207
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 199
Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study 199
Autoimmune hepatitis in a patient affected by neuromyelitis optica: A new association. 198
Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab 198
Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42] 198
Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature 195
Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI 189
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer 186
Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study 185
Seasonal Allergic Rhinitis Symptoms in Relation to COVID-19 179
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. 177
EGPA Phenotyping: Not Only ANCA, but Also Eosinophils 176
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study 176
Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis 173
Primary antibody deficiencies represent an underestimated comorbidity in asthma patients: efficacy of immunoglobulin replacement therapy in asthma control 166
Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience 166
Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. 166
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 166
Baseline Eosinophil Count as a Potential Clinical Biomarker for Clinical Complexity in EGPA: A Real-Life Experience 159
Effectiveness of tocilizumab in hospitalized moderate-to-severe COVID-19 patients: a real-life study 159
Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis 159
Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity 158
Asthma remission one, none and one-hundred thousand: the relevance of the patient’s view 155
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice 154
Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: a two-year real-life experience 153
Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma 152
Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis 149
Alert Card for Patients on Biologicals and Immunosuppressives: An EAACI Position Paper 147
Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. 145
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 143
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 143
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 141
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 139
Case Report: A child with NFKB1 haploinsufficiency explaining the linkage between immunodeficiency and short stature 136
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 134
Sustained Efficacy and Low Rate of Adverse Events of Dupilumab in Type‐2 CRSwNP Over 48 Months 133
Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC) 131
Asthma phenotype can be influenced by recurrent respiratory infections in patients with primary antibody deficiency: the impact of Ig therapy 121
Mechanisms of Action of Ig Preparations: Immunomodulatory and Anti-Inflammatory Effects 101
Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy 88
Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR 71
A real-life multicenter experience for the post-pandemic management of hypersensitivity reactions to Covid-19 vaccines 55
Dupilumab in Chronic Rhinosinusitis With Nasal Polyps Patients: Impact on Tissue Eosinophilic Inflammation and Eosinophil Subphenotypes 54
Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review 42
Efficacy and safety of mepolizumab in the treatment of CRSwNP in the real-life setting: a review of the literature 37
Eosinophilic vasculitis of aortic valve in EGPA: a life-threatening onset of disease 33
Immunogenicity in Fabry Disease: Current Issues, Coping Strategies, and Future Directions 28
Rituximab in the treatment of anti-HMGCR immune-mediated necrotizing myopathy: Two cases successfully treated 27
The Neglected Older Adults in Hereditary Angioedema: Insights From the ITACA Registry 20
null 12
Totale 12.024
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.606
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.606
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022267 0 0 0 11 11 29 18 34 16 24 47 77
2022/2023862 65 186 49 43 51 140 110 48 94 15 32 29
2023/2024519 11 29 61 30 50 56 36 99 14 43 58 32
2024/20252.909 96 282 171 484 713 331 78 185 167 89 123 190
2025/20264.609 545 515 441 416 476 152 473 197 327 319 262 486
2026/2027904 184 174 369 177 0 0 0 0 0 0 0 0
Totale 12.024